[go: up one dir, main page]

CY1111353T1 - Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης - Google Patents

Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης

Info

Publication number
CY1111353T1
CY1111353T1 CY20111100314T CY111100314T CY1111353T1 CY 1111353 T1 CY1111353 T1 CY 1111353T1 CY 20111100314 T CY20111100314 T CY 20111100314T CY 111100314 T CY111100314 T CY 111100314T CY 1111353 T1 CY1111353 T1 CY 1111353T1
Authority
CY
Cyprus
Prior art keywords
compounds
kalalidis
porcelain
medicine
treatment
Prior art date
Application number
CY20111100314T
Other languages
English (en)
Inventor
Delso Miguel Angel Izquierdo
Original Assignee
Pharma Mar, S.A.U.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar, S.A.U. filed Critical Pharma Mar, S.A.U.
Publication of CY1111353T1 publication Critical patent/CY1111353T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Οι ενώσεις κααλαλίδης, συγκεκριμένα η κααλαλίδη F, χρησιμοποιούνται σε μέθοδο για τη θεραπεία θηλαστικού που πάσχει από δερματική νόσο αποφεύγοντας την τοξικότητα και οδηγώντας σε κλινική βελτίωση.
CY20111100314T 2003-02-26 2011-03-22 Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης CY1111353T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0304367.6A GB0304367D0 (en) 2003-02-26 2003-02-26 Methods for treating psoriasis
EP04714847A EP1596879B1 (en) 2003-02-26 2004-02-26 Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis

Publications (1)

Publication Number Publication Date
CY1111353T1 true CY1111353T1 (el) 2015-08-05

Family

ID=9953685

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100314T CY1111353T1 (el) 2003-02-26 2011-03-22 Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης

Country Status (17)

Country Link
US (2) US7323444B2 (el)
EP (1) EP1596879B1 (el)
JP (1) JP4800194B2 (el)
AT (1) ATE492285T1 (el)
AU (1) AU2004216443B2 (el)
CA (1) CA2516458C (el)
CY (1) CY1111353T1 (el)
DE (1) DE602004030661D1 (el)
DK (1) DK1596879T3 (el)
ES (1) ES2358018T3 (el)
GB (1) GB0304367D0 (el)
MX (1) MXPA05009029A (el)
NZ (1) NZ541493A (el)
PT (1) PT1596879E (el)
RU (1) RU2356908C2 (el)
SI (1) SI1596879T1 (el)
WO (1) WO2004075910A1 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
WO2009052379A2 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
EP2252315A1 (en) * 2008-01-30 2010-11-24 Pharma Mar, S.A. Improved antitumoral treatments
EP2262522A1 (en) * 2008-03-07 2010-12-22 Pharma Mar, S.A. Improved antitumoral treatments
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
JPS6178719A (ja) * 1984-09-25 1986-04-22 Tanabe Seiyaku Co Ltd 総合輸液剤
GR870129B (en) 1987-01-27 1987-02-04 Giatzidis Ippokratis Stable bicarbonate - glycylglycine dialysate for hemodialysis and peritoneal dialysis
US4853388A (en) * 1987-05-15 1989-08-01 Pearlman Dale L Method for treating psoriasis with cytotoxic agents
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
DK0531472T3 (da) * 1991-03-06 2003-12-01 Merck Patent Gmbh Humaniserede monoklonale antistoffer
ES2161697T3 (es) * 1991-11-19 2001-12-16 Amylin Pharmaceuticals Inc Peptidos agonistas de amilina y usos de los mismos.
US5849704A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9302046D0 (en) * 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
US5932189A (en) 1994-07-29 1999-08-03 Diatech, Inc. Cyclic peptide somatostatin analogs
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JP3927248B2 (ja) 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
EP0912559B1 (en) * 1996-07-13 2002-11-06 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6489136B1 (en) 1997-05-09 2002-12-03 The General Hospital Corporation Cell proliferation related genes
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
US6200598B1 (en) * 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
WO2000031048A1 (en) * 1998-11-19 2000-06-02 Warner-Lambert Company N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
CA2406743A1 (en) 2000-04-28 2001-11-08 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
MXPA03003704A (es) * 2000-10-31 2004-05-04 Pharma Mar Sa Formulacion de kahalalide f.
US20050054555A1 (en) 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
AU2002334203C1 (en) 2001-10-19 2008-10-09 Pharma Mar, S.A. Kahalalide compounds for use in cancer therapy
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
CN100591691C (zh) * 2002-10-18 2010-02-24 马尔药品公司 新型抗肿瘤化合物
US7507708B2 (en) * 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
GB0321066D0 (en) 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds

Also Published As

Publication number Publication date
MXPA05009029A (es) 2005-11-23
JP4800194B2 (ja) 2011-10-26
NZ541493A (en) 2008-07-31
CA2516458A1 (en) 2004-09-10
ATE492285T1 (de) 2011-01-15
US7323444B2 (en) 2008-01-29
JP2007527851A (ja) 2007-10-04
US20070032412A1 (en) 2007-02-08
WO2004075910A1 (en) 2004-09-10
AU2004216443B2 (en) 2009-03-19
CA2516458C (en) 2012-11-27
SI1596879T1 (sl) 2011-07-29
DK1596879T3 (da) 2011-04-11
PT1596879E (pt) 2011-02-23
ES2358018T3 (es) 2011-05-04
RU2356908C2 (ru) 2009-05-27
GB0304367D0 (en) 2003-04-02
AU2004216443A1 (en) 2004-09-10
DE602004030661D1 (de) 2011-02-03
EP1596879A1 (en) 2005-11-23
US20080090757A1 (en) 2008-04-17
RU2005115102A (ru) 2006-02-27
EP1596879B1 (en) 2010-12-22

Similar Documents

Publication Publication Date Title
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
MX2010004074A (es) Combinacion 059.
LTC1620113I2 (lt) Ivermektino topinė kompozicija, skirta dermatologinių susirgimų gydymui
EA200901555A1 (ru) Композиция местного применения по уходу за кожей и способ лечения
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
EA200802213A1 (ru) Способы лечения заболеваний крови
EA201000914A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
ATE448232T1 (de) Substituierte heterozyklen
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
NO20071798L (no) Dermalt pafore formuleringer for behandling av hudsykdommer i dyr
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE502004008819D1 (de) Medikament zur wachstumsinhibierung von tumoren
ATE410155T1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
EA200401319A1 (ru) Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине
NO20050718L (no) Topikal behandling av hudsykdommer
EA200501310A1 (ru) Производные бензолсульфонамидов, способ их получения и их применение для лечения боли
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE556134T1 (de) Mesenchymstammzellen und verwendungendafür
ATE535237T1 (de) Verwendung von fts zur behandlung von malignen erkrankungen
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
ATE431348T1 (de) Thiaepothilone zur behandlung von krebserkrankungen
DK1904511T3 (da) Homogemcitabin